Journal article
Intravenous co-amoxiclav to prevent infection after operative vaginal delivery: the ANODE RCT
Marian Knight, Virginia Chiocchia, Christopher Partlett, Oliver Rivero-Arias, Xinyang Hua, Ursula Bowler, James Gray, Shan Gray, Kim Hinshaw, Aethele Khunda, Philip Moore, Linda Mottram, Nelly Owino, Dharmintra Pasupathy, Julia Sanders, Abdul H Sultan, Ranee Thakar, Derek Tuffnell, Louise Linsell, Edmund Juszczak Show all
HEALTH TECHNOLOGY ASSESSMENT | NIHR JOURNALS LIBRARY | Published : 2019
DOI: 10.3310/hta23540
Abstract
BACKGROUND: Sepsis is a leading cause of direct and indirect maternal death in both the UK and globally. All forms of operative delivery are associated with an increased risk of sepsis, and the National Institute for Health and Care Excellence's guidance recommends the use of prophylactic antibiotics at all caesarean deliveries, based on substantial randomised controlled trial evidence of clinical effectiveness. A Cochrane review, updated in 2017 (Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Antibiotic prophylaxis for operative vaginal delivery. Cochrane Database Syst Rev 2017;8:CD004455), identified only one small previous trial of prophylactic antibiotics following operative v..
View full abstractGrants
Awarded by National Institute for Health Research Health Technology Assessment programme
Funding Acknowledgements
This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 54. See the National Institute for Health Research Journals Library website for further project information.